Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman Sells 434 Shares of Stock

Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman sold 434 shares of the stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $95.33, for a total transaction of $41,373.22. Following the completion of the transaction, the chief financial officer now directly owns 54,166 shares of the company’s stock, valued at $5,163,644.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $96.80 on Friday. Glaukos Co. has a 1 year low of $45.38 and a 1 year high of $97.77. The firm’s 50 day moving average price is $90.83 and its 200 day moving average price is $79.16. The company has a debt-to-equity ratio of 0.77, a quick ratio of 4.78 and a current ratio of 5.34.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The firm had revenue of $82.40 million for the quarter, compared to analyst estimates of $81.00 million. During the same quarter last year, the business posted ($0.53) EPS. The firm’s revenue was up 15.7% compared to the same quarter last year. Equities analysts forecast that Glaukos Co. will post -2.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GKOS. StockNews.com cut shares of Glaukos from a “hold” rating to a “sell” rating in a report on Tuesday, February 27th. JPMorgan Chase & Co. raised shares of Glaukos from a “neutral” rating to an “overweight” rating and increased their target price for the company from $66.00 to $91.00 in a report on Thursday, December 21st. Citigroup increased their target price on shares of Glaukos from $107.00 to $120.00 and gave the company a “buy” rating in a report on Monday, March 25th. Stifel Nicolaus reiterated a “buy” rating and issued a $110.00 price target on shares of Glaukos in a research report on Wednesday. Finally, Wells Fargo & Company increased their price target on shares of Glaukos from $83.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and an average target price of $98.30.

Institutional Trading of Glaukos

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Glaukos by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 5,380,720 shares of the medical instruments supplier’s stock valued at $286,470,000 after purchasing an additional 23,473 shares during the last quarter. Brown Capital Management LLC boosted its holdings in shares of Glaukos by 3.4% in the 4th quarter. Brown Capital Management LLC now owns 2,697,794 shares of the medical instruments supplier’s stock valued at $214,448,000 after purchasing an additional 89,420 shares during the last quarter. Braidwell LP boosted its holdings in shares of Glaukos by 8.7% in the 1st quarter. Braidwell LP now owns 1,806,651 shares of the medical instruments supplier’s stock valued at $90,513,000 after purchasing an additional 144,800 shares during the last quarter. State Street Corp boosted its holdings in shares of Glaukos by 1.8% in the 2nd quarter. State Street Corp now owns 1,782,347 shares of the medical instruments supplier’s stock valued at $126,921,000 after purchasing an additional 31,471 shares during the last quarter. Finally, Fred Alger Management LLC boosted its holdings in shares of Glaukos by 9.2% in the 3rd quarter. Fred Alger Management LLC now owns 1,780,690 shares of the medical instruments supplier’s stock valued at $133,997,000 after purchasing an additional 150,102 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.